NASDAQ:SDGR Schrödinger (SDGR) Stock Price, News & Analysis $26.54 +2.05 (+8.37%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Schrödinger Stock (NASDAQ:SDGR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Schrödinger alerts:Sign Up Key Stats Today's Range$24.31▼$26.8650-Day Range$17.97▼$26.5452-Week Range$16.60▼$28.47Volume3.37 million shsAverage Volume801,870 shsMarket Capitalization$1.94 billionP/E RatioN/ADividend YieldN/APrice Target$32.29Consensus RatingBuy Company OverviewSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Read More… Remove Ads Schrödinger Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreSDGR MarketRank™: Schrödinger scored higher than 31% of companies evaluated by MarketBeat, and ranked 442nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingSchrödinger has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSchrödinger has only been the subject of 2 research reports in the past 90 days.Read more about Schrödinger's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Schrödinger are expected to grow in the coming year, from ($2.37) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Schrödinger is -11.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Schrödinger is -11.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSchrödinger has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Schrödinger's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.03% of the float of Schrödinger has been sold short.Short Interest Ratio / Days to CoverSchrödinger has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Schrödinger has recently increased by 5.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSchrödinger does not currently pay a dividend.Dividend GrowthSchrödinger does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.03% of the float of Schrödinger has been sold short.Short Interest Ratio / Days to CoverSchrödinger has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Schrödinger has recently increased by 5.06%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.92 News SentimentSchrödinger has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Schrödinger this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for SDGR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Schrödinger to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Schrödinger insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $119,484.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Schrödinger is held by insiders.Percentage Held by Institutions79.05% of the stock of Schrödinger is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Schrödinger's insider trading history. Receive SDGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Schrödinger and its competitors with MarketBeat's FREE daily newsletter. Email Address SDGR Stock News HeadlinesSchrödinger unterstützt FDA-Initiative zur Reduzierung von TierversuchenApril 14 at 4:52 PM | de.investing.comSchrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other DrugsApril 14 at 11:51 AM | finance.yahoo.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 15, 2025 | Porter & Company (Ad)Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other DrugsApril 14 at 8:00 AM | businesswire.comSchrödinger (NASDAQ:SDGR) Shares Gap Up - Here's WhyApril 13 at 2:49 AM | americanbankingnews.comSchrödinger Sees Unusually High Options Volume (NASDAQ:SDGR)April 13 at 1:24 AM | americanbankingnews.comSchrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)April 12 at 11:01 AM | seekingalpha.comSchrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth PlansMarch 27, 2025 | finance.yahoo.comSee More Headlines SDGR Stock Analysis - Frequently Asked Questions How have SDGR shares performed this year? Schrödinger's stock was trading at $19.29 at the beginning of 2025. Since then, SDGR shares have increased by 37.6% and is now trading at $26.54. View the best growth stocks for 2025 here. How were Schrödinger's earnings last quarter? Schrödinger, Inc. (NASDAQ:SDGR) posted its quarterly earnings data on Wednesday, February, 26th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.20. The company earned $88.32 million during the quarter, compared to analysts' expectations of $83.20 million. Schrödinger had a negative trailing twelve-month return on equity of 35.77% and a negative net margin of 91.84%. Read the conference call transcript. When did Schrödinger IPO? Schrödinger (SDGR) raised $150 million in an IPO on Thursday, February 6th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Securities, Jefferies and BMO Capital Markets acted as the underwriters for the IPO. Who are Schrödinger's major shareholders? Schrödinger's top institutional shareholders include GAMMA Investing LLC (0.17%), IMC Chicago LLC, Yousif Capital Management LLC (0.03%) and Harbor Capital Advisors Inc. (0.02%). Insiders that own company stock include Ramy Farid, Kenneth Patrick Lorton, Geoffrey Craig Porges, Margaret Dugan, Yvonne Tran, Jenny Herman, Robert Lorne Abel and Nancy Thornberry. View institutional ownership trends. How do I buy shares of Schrödinger? Shares of SDGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Schrödinger own? Based on aggregate information from My MarketBeat watchlists, some other companies that Schrödinger investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings2/26/2025Today4/15/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SDGR CIK1490978 Webwww.schrodinger.com Phone212-295-5800FaxN/AEmployees790Year FoundedN/APrice Target and Rating Average Stock Price Target$32.29 High Stock Price Target$45.00 Low Stock Price Target$27.00 Potential Upside/Downside+21.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$40.72 million Net Margins-91.84% Pretax Margin-92.05% Return on Equity-35.77% Return on Assets-24.51% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio4.11 Sales & Book Value Annual Sales$207.54 million Price / Sales9.34 Cash Flow$0.71 per share Price / Cash Flow37.42 Book Value$7.60 per share Price / Book3.49Miscellaneous Outstanding Shares73,038,000Free Float66,593,000Market Cap$1.94 billion OptionableOptionable Beta1.77 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:SDGR) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Schrödinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Schrödinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.